David Altarac
-
- Antibiotic Use and Resistance 6
- Clinical Biochemistry top 1%
- Bacterial Identification and Susceptibility Testing 2
- Molecular Medicine top 2%
- Antibiotic Resistance in Bacteria 7
- Infectious Diseases top 5%
- Antimicrobial Resistance in Staphylococcus 2
- Tuberculosis Research and Epidemiology 1
- Endocrinology top 10%
-
- Antibiotics Pharmacokinetics and Efficacy 5
-
- Bacterial biofilms and quorum sensing 2
-
- COVID-19 epidemiological studies 1
- Co-authors
- S HandwergerJohannes WolffKavindra V. SinghB. RaucherBarbara E. MurrayBradford L. WaltersDavid C. PerlmanV. J. McAuliffe
- Journals
- Open Forum Infectious Diseases (4 papers)Clinical Infectious Diseases (3 papers)Journal of Public Health Management and Practice (1 paper)
- Partner nations
- United StatesChina
In The Last Decade
David Altarac
12 papers receiving 644 citations
Hit Papers
Peers
Comparison fields: 5 of 60
- Applied Microbiology and Biotechnology 103
- Clinical Biochemistry 299
- Molecular Medicine 214
- Infectious Diseases 405
- Endocrinology 59
Countries citing papers authored by David Altarac
This map shows the geographic impact of David Altarac's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Altarac with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Altarac more than expected).
Fields of papers citing papers by David Altarac
This network shows the impact of papers produced by David Altarac. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Altarac. The network helps show where David Altarac may publish in the future.
Co-authorship network
The 25 scholars most cited alongside David Altarac, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 7 | |
| 2 | Efficacy and safety of sulbactam–durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii–calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)breakdown → | 2023 | 146 |
| 3 | 2023 | 5 | |
| 4 | 2022 | 1 | |
| 5 | 2022 | 1 | |
| 6 | 2022 | 3 | |
| 7 | 2022 | 1 | |
| 8 | 2021 | 23 | |
| 9 | 1995 | 4 | |
| 10 | 1993 | 369 | |
| 11 | 1992 | 88 | |
| 12 | 1991 | 32 |
About David Altarac
David Altarac is a scholar working on Applied Microbiology and Biotechnology, Molecular Medicine, Pharmacology, Clinical Biochemistry and Modeling and Simulation, having authored 12 papers that have together received 680 indexed citations. Recurring topics across this work include Antibiotic Resistance in Bacteria (7 papers), Antibiotic Use and Resistance (6 papers), Antibiotics Pharmacokinetics and Efficacy (5 papers), Bacterial Identification and Susceptibility Testing (2 papers), Bacterial biofilms and quorum sensing (2 papers), Antimicrobial Resistance in Staphylococcus (2 papers), COVID-19 epidemiological studies (1 paper) and Tuberculosis Research and Epidemiology (1 paper). The work is most often cited by research in Applied Microbiology and Biotechnology (103 citations), Clinical Biochemistry (299 citations), Molecular Medicine (214 citations), Infectious Diseases (405 citations) and Endocrinology (59 citations). David Altarac has collaborated with scholars based in United States and China. Frequent co-authors include S Handwerger, Johannes Wolff, Kavindra V. Singh, B. Raucher, Barbara E. Murray, Bradford L. Walters, David C. Perlman, V. J. McAuliffe, Khurram Rana and Bin Du. Their work appears in journals such as Open Forum Infectious Diseases, Clinical Infectious Diseases, Journal of Public Health Management and Practice, American Journal of Hematology and The Lancet Infectious Diseases.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.